Susanna Gatti High Sells 40,000 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Susanna Gatti High sold 40,000 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $33.36, for a total value of $1,334,400.00. Following the sale, the chief operating officer now directly owns 148,792 shares of the company’s stock, valued at $4,963,701.12. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Susanna Gatti High also recently made the following trade(s):

• On Monday, June 10th, Susanna Gatti High sold 80,000 shares of Dyne Therapeutics stock. The shares were sold at an average price of $30.24, for a total value of $2,419,200.00.
• On Thursday, May 16th, Susanna Gatti High sold 2,738 shares of Dyne Therapeutics stock. The shares were sold at an average price of $28.27, for a total transaction of $77,403.26.

Dyne Therapeutics Trading Up 2.1 %

Shares of DYN stock opened at $33.69 on Friday. Dyne Therapeutics, Inc. has a 12 month low of $6.40 and a 12 month high of $35.98. The stock has a 50 day moving average of $28.08 and a 200-day moving average of $22.70.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.81) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.81). As a group, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale increased its holdings in Dyne Therapeutics by 50.0% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 60,000 shares of the company’s stock valued at $1,710,000 after buying an additional 20,000 shares during the period. RA Capital Management L.P. bought a new stake in Dyne Therapeutics in the first quarter valued at about $140,666,000. Artal Group S.A. raised its position in Dyne Therapeutics by 24.6% in the first quarter. Artal Group S.A. now owns 1,517,960 shares of the company’s stock worth $43,095,000 after purchasing an additional 300,000 shares in the last quarter. California State Teachers Retirement System lifted its stake in Dyne Therapeutics by 29.9% during the first quarter. California State Teachers Retirement System now owns 44,784 shares of the company’s stock worth $1,271,000 after purchasing an additional 10,317 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in Dyne Therapeutics by 23,512.0% during the first quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock valued at $75,915,000 after purchasing an additional 2,663,910 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

DYN has been the subject of several analyst reports. Jefferies Financial Group lifted their price objective on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Monday, May 20th. Chardan Capital boosted their price target on Dyne Therapeutics from $31.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, May 21st. Piper Sandler increased their price objective on Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Oppenheimer reissued an “outperform” rating and issued a $47.00 price objective on shares of Dyne Therapeutics in a research note on Monday, May 6th. Finally, Morgan Stanley assumed coverage on Dyne Therapeutics in a research report on Tuesday, April 30th. They set an “overweight” rating and a $40.00 target price for the company. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.78.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.